Institut Català de la Salut
[Mayneris-Perxachs J] Department of Diabetes, Endocrinology and Nutrition, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IdibGi), Girona, Spain. Department of Endocrinology and Nutrition, Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain. [Russo MF] Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Università Cattolica del Sacro Cuore Rome, Rome, Italy. [Ramos R] Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain. Vascular Health Research Group of Girona (ISV-Girona). Jordi Gol Institute for Primary Care Research (Institut Universitari per a la Recerca en AtencióPrimària Jordi Gol I Gurina -IDIAPJGol), Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain. [de Hollanda A] Department of Endocrinology & Nutrition, Hospital Clínic Barcelona, Diabetes Unit, Barcelona, Spain. Department of Endocrinology and Nutrition, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Armengou A] Departament de Medicina Interna, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Rottoli M] Department of Surgery, Diabetology and Otolaryngology, Surgery of the Alimentary Tract and Centre for the Study and Research of Treatment for Morbid Obesity, Bologna, Italy. Infectious Diseases Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Sant'Orsola Policlinic, Bologna, Italy. [Arnoriaga Rodríguez M] Department of Diabetes, Endocrinology and Nutrition, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IdibGi), Girona, Spain. Department of Endocrinology and Nutrition, Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain. Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain. [Comas-Cufí M] Vascular Health Research Group of Girona (ISV-Girona). Jordi Gol Institute for Primary Care Research (Institut Universitari per a la Recerca en AtencióPrimària Jordi Gol I Gurina -IDIAPJGol), Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain. [Fages E] Vascular Health Research Group of Girona (ISV-Girona). Jordi Gol Institute for Primary Care Research (Institut Universitari per a la Recerca en AtencióPrimària Jordi Gol I Gurina -IDIAPJGol), Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, Catalonia, Spain. [De Genover Gil A, Castro Guardiola A] Department of Internal Medicine, Service of Internal Medicine, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Fernández-Real JM] Department of Diabetes, Endocrinology and Nutrition, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IdibGi), Girona, Spain. Department of Endocrinology and Nutrition, Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain. Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain
Hospital Universitari de Girona Dr Josep Trueta
2024-03-14T11:26:59Z
2024-03-14T11:26:59Z
2021-11-02
Covid-19; Hemoglobina; Hiperglucèmia; Obesitat mòrbida
Covid-19; Hemoglobina; Hiperglucemia; Obesidad mórbida
Covid-19; Hemoglobin; Hyperglycemia; Morbid obesity
Background: Hyperglycemia and obesity are associated with a worse prognosis in subjects with COVID-19 independently. Their interaction as well as the potential modulating effects of additional confounding factors is poorly known. Therefore, we aimed to identify and evaluate confounding factors affecting the prognostic value of obesity and hyperglycemia in relation to mortality and admission to the intensive care unit (ICU) due to COVID-19. Methods: Consecutive patients admitted in two Hospitals from Italy (Bologna and Rome) and three from Spain (Barcelona and Girona) as well as subjects from Primary Health Care centers. Mortality from COVID-19 and risk for ICU admission were evaluated using logistic regression analyses and machine learning (ML) algorithms. Results: As expected, among 3,065 consecutive patients, both obesity and hyperglycemia were independent predictors of ICU admission. A ML variable selection strategy confirmed these results and identified hyperglycemia, blood hemoglobin and serum bilirubin associated with increased mortality risk. In subjects with blood hemoglobin levels above the median, hyperglycemic and morbidly obese subjects had increased mortality risk than normoglycemic individuals or non-obese subjects. However, no differences were observed among individuals with hemoglobin levels below the median. This was particularly evident in men: those with severe hyperglycemia and hemoglobin concentrations above the median had 30 times increased mortality risk compared with men without hyperglycemia. Importantly, the protective effect of female sex was lost in subjects with increased hemoglobin levels. Conclusions: Blood hemoglobin substantially modulates the influence of hyperglycemia on increased mortality risk in patients with COVID-19. Monitoring hemoglobin concentrations seem of utmost importance in the clinical settings to help clinicians in the identification of patients at increased death risk.
We thank CERCA Programme/Generalitat de Catalunya for institutional support. This study was in part supported by the Spanish Plan Nacional de I+D+i 2013‐2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001) ‐ co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Programme Intelligent Growth 2014‐2020. CIBERobn is an initiative of ISCIII. Partially supported by FIS Grant (PI17/01167), ISCIII. JM-P is funded by the Miguel Servet Program from the Instituto de Salud Carlos III (ISCIII CP18/00009), co-funded by the European Social Fund “Investing in your future”
Article
Published version
English
COVID-19 (Malaltia) - Epidemiologia; Hemoglobina; Hiperglucèmia; Obesitat mòrbida; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; Other subheadings::Other subheadings::Other subheadings::/epidemiology; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Hemoglobins::Hemoglobin A; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia; DISEASES::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity::Obesity, Morbid; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::hemoglobinas::hemoglobina A; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperglucemia; ENFERMEDADES::enfermedades nutricionales y metabólicas::trastornos nutricionales::hipernutrición::obesidad::obesidad mórbida
Frontiers Media
Frontiers in Endocrinology;12
https://doi.org/10.3389/fendo.2021.741248
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/